1. Anti-infection
  2. Influenza Virus
  3. Oseltamivir phosphate

Oseltamivir phosphate (Synonyms: GS 4104)

Cat. No.: HY-17016 Purity: 99.85%
Handling Instructions

Oseltamivir phosphate (GS 4104) is a neuraminidase inhibitor recommended for the treatment and prophylaxis of influenza A and B.

For research use only. We do not sell to patients.

Oseltamivir phosphate Chemical Structure

Oseltamivir phosphate Chemical Structure

CAS No. : 204255-11-8

Size Price Stock Quantity
Free Sample (0.5-1 mg)   Apply now  
10 mM * 1 mL in DMSO USD 66 In-stock
Estimated Time of Arrival: December 31
100 mg USD 60 In-stock
Estimated Time of Arrival: December 31
500 mg USD 102 In-stock
Estimated Time of Arrival: December 31
1 g   Get quote  
5 g   Get quote  

* Please select Quantity before adding items.

Customer Review

Based on 4 publication(s) in Google Scholar

Other Forms of Oseltamivir phosphate:

Top Publications Citing Use of Products
  • Biological Activity

  • Protocol

  • Technical Information

  • Purity & Documentation

  • References

Description

Oseltamivir phosphate (GS 4104) is a neuraminidase inhibitor recommended for the treatment and prophylaxis of influenza A and B.

IC50 & Target

Influenza A and B[1]

In Vitro

Oseltamivir phosphate (OP) is a prodrug that is readily absorbed from the gastrointestinal tract after oral administration and is extensively converted predominantly by hepatic esterases to Oseltamivir carboxylate (OC)[1]. Oseltamivir phosphate is a widely used anti-influenza sialidase inhibitor. The metabolic activity of CMA07 and CMT-U27 cell lines is significantly decreased with 305 μM Oseltamivir phosphate treatment (p=0.005 and p<0.0001 respectively) using One Way ANOVA testes. In contrast, no statistically significant alterations are observed with 0.305 μM (p=0.9781), 3.05 μM (p=0.7436) and 30.5 μM (p=0.9623) of Oseltamivir phosphate treatments when compare with control cells. Finally, to assess the effect of Oseltamivir phosphate on CMA07 and CMT-U27 programmed cell death, and given that 305 μM Oseltamivir phosphate treatment impaired cell metabolic activity, a programmed cell death measurement is performed with the TUNEL assay. Twenty-four hour Oseltamivir phosphate treatment, specifically at 305 μM, significantly increases CMA07 (p=0.001) and CMT-U27 (p=0.0002) DNA fragmentation, suggesting promotion of programmed cell death, when compare with lower Oseltamivir concentrations, or with PBS[2].

In Vivo

Oseltamivir phosphate-treated mice present significantly more inflammatory infiltrate in primary tumors (p=0.01). Ki-67 antigen and caspase-3 protein are used to assess CMT-U27 xenograft tumor cell proliferation and apoptosis respectively. Virtually no differences are found in Ki-67 and caspase 3 (p=0.2) expression between Oseltamivir-treated and non-treated mice[2].

Clinical Trial
Storage
Powder -20°C 3 years
  4°C 2 years
In solvent -80°C 6 months
  -20°C 1 month
Solvent & Solubility
In Vitro: 

DMSO : ≥ 150 mg/mL (365.50 mM)

H2O : 125 mg/mL (304.58 mM; Need ultrasonic and warming)

*"≥" means soluble, but saturation unknown.

Preparing
Stock Solutions
Concentration Solvent Mass 1 mg 5 mg 10 mg
1 mM 2.4366 mL 12.1832 mL 24.3665 mL
5 mM 0.4873 mL 2.4366 mL 4.8733 mL
10 mM 0.2437 mL 1.2183 mL 2.4366 mL
*Please refer to the solubility information to select the appropriate solvent.
In Vivo:
  • 1.

    Oseltamivir phosphate is prepared in PBS[3].

References
Cell Assay
[2]

CMA07 and CMT-U27 cells are cultured in 24-well plates in triplicate for each condition: 0.305 μM, 3.05 μM, 30.5 μM and 305 μM Oseltamivir phosphate and PBS is used as control. Cells are counted every day for 7 days in a Neubauer’s chamber in a 1:2 dilution of cells in 0.4% trypan blue and cell count is done using the volume conversion factor for 1 mm3, which is 1×104. This assay is repeated 3 times and growth curves are traced[2].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Administration
[2]

Mice[2]
Female NIH(S)II-nu/nu nude mice, aged 4-6 weeks, are orthotopically inoculated with 1×106 viable CMT-U27 canine breast cancer cells in the mammary fat pad using a 25 gauge needle. A total of 8 mice are inoculated. When nodules reached a volume of approximately 500 mm3, mice (n=8) are randomized and divided into control group (n=4) and treatment group (n=4).The animals receive intraperitoneally (IP) dailly either 100 μL of PBS (control group) or 100mg/Kg of Oseltamivir phosphate, diluted in PBS (treatment group) until time of death. Tumor size is measured using calipers, and tumor volume (mm3) is estimated by width×length×height.

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

References
Molecular Weight

410.40

Formula

C₁₆H₃₁N₂O₈P

CAS No.

204255-11-8

SMILES

O=C(OCC)C1=C[[email protected]]([[email protected]@H]([[email protected]](C1)N)NC(C)=O)OC(CC)CC.OP(O)(O)=O

Shipping

Room temperature in continental US; may vary elsewhere

Purity: 99.85%

  • Molarity Calculator

  • Dilution Calculator

The molarity calculator equation

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass   Concentration   Volume   Molecular Weight *
= × ×

The dilution calculator equation

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
× = ×
C1   V1   C2   V2

Inquiry Online

Your information is safe with us. * Required Fields.

Product name

 

Salutation

Applicant name *

 

Email address *

Phone number *

 

Organization name *

Country or Region *

 

Requested quantity *

Remarks

Bulk Inquiry

Inquiry Information

Product Name:
Oseltamivir phosphate
Cat. No.:
HY-17016
Quantity:

Oseltamivir phosphate

Cat. No.: HY-17016